LOGO
LOGO

Breaking News

Pre-market Movers For Dec 7 (NFLX, ACRX, AMRN, AVGO, ZGNX)

By RTTNews Staff Writer   ✉  | Published:  | Google News Follow Us  | Join Us
rttnewslogo20mar2024

Gainers:

AcelRx Pharmaceuticals, Inc. (ACRX) is rising 5 percent to $3.48. The company announced that it has priced its underwritten public offering of 12.5 million common shares at $3.31 per share.

Decliners:

Netflix, Inc. (NFLX) is down 0.36 percent to $85.86. Netflix disclosed that the company and its chief executive Reed Hastings each received a Wells Notice from SEC Staff about its intent to recommend to the SEC to bring a civil action for violations of fair disclosure related to statement he posted in Facebook in July about the 1 billion hour service usage.

Amarin Corporation plc (AMRN) is plunging 19 percent to $9.71. The company announced $100 million non-equity financing through a hybrid debt-like instrument. The company also noted that it is continuing to assess strategic options.

Avago Technologies Ltd. (AVGO) is falling over 2 percent to $34.30. The company announced the sale of 21.49 million ordinary shares by certain existing shareholders, including its President and chief executive and entities affiliated with certain directors.

Trading halt:

Trading in shares of Zogenix, Inc. (ZGNX) was halted.

For comments and feedback contact: editorial@rttnews.com

Business News

Looking to Invest in the Best Biotech Stocks? Subscribe to RTT Biotech Investor.
Global Economics Weekly Update - Jun 01 - Jun 05, 2026

June 05, 2026 16:18 ET
A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.

RELATED NEWS
Latest Updates on COVID-19